BRIEF published on 01/19/2026 at 07:35, 1 month 17 days ago FDA Reviews Advicenne's Sibnayal® for U.S. Approval FDA Advicenne Sibnayal® DRTA PDUFA Date
BRIEF published on 01/19/2026 at 07:35, 1 month 17 days ago Advicenne: FDA-approved marketing application for Sibnayal® FDA ATRd Advicenna Sibnayal® PDUFA
PRESS RELEASE published on 01/19/2026 at 07:30, 1 month 17 days ago Inside Information / Other news releases FDA accepts Advicenne's Marketing Authorization Application for Sibnayal® for dRTA treatment in the US, with a PDUFA decision target date of September 3rd, 2026 FDA Advicenne Sibnayal DRTA PDUFA
BRIEF published on 01/12/2026 at 07:35, 1 month 24 days ago Renewal of the marketing authorization for Sibnayal® in the European Union Kidney Disease EMA Advicenna AMM Sibnayal®
BRIEF published on 11/04/2025 at 11:35, 4 months 1 day ago Advicenne submits Sibnayal® to the US FDA FDA Advicenna Sibnayal® Renal Tubular Acidosis Registration Filing
PRESS RELEASE published on 11/04/2025 at 11:30, 4 months 1 day ago Inside Information / Other news releases Advicenne submits registration application for Sibnayal® in dRTA treatment to US FDA, designated orphan drug. Evaluation process expected to take 12 months Advicenne Sibnayal® US FDA DRTA Treatment Registration Application
BRIEF published on 09/19/2025 at 18:05, 5 months 15 days ago Advicenne: Half-year results in 2025 and outlook Financial Results Outlook Turnover United States Sibnayal®
BRIEF published on 07/28/2025 at 07:35, 7 months 8 days ago Advicenne Secures Marketing Authorization for Sibnayal® in Saudi Arabia Saudi Arabia Advicenne Reimbursement Sibnayal® DRTA
PRESS RELEASE published on 07/28/2025 at 07:30, 7 months 8 days ago Inside Information / Other news releases Advicenne obtains marketing authorization and reimbursement for Sibnayal® in Saudi Arabia, a fixed combination for rare kidney diseases, in collaboration with Taïba Healthcare Saudi Arabia Advicenne Reimbursement Marketing Authorization Sibnayal
BRIEF published on 07/25/2025 at 07:35, 7 months 11 days ago Advicenne Announces 9% Revenue Growth for H1 2025 Growth Turnover Advicenna Sibnayal® Pharmaceutical Markets
Published on 03/05/2026 at 13:40, 12 minutes ago Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Published on 03/05/2026 at 13:30, 22 minutes ago Vox Royalty Provides 2026 Guidance and Increases Quarterly Dividend
Published on 03/05/2026 at 13:30, 22 minutes ago Nextech3D.ai Expands AI Event Technology Into New Markets and Implements 20%-30% Enterprise Price Increase
Published on 03/05/2026 at 13:00, 52 minutes ago Revolve Signs Definitive Agreements for Portfolio of 16 Distributed Generation Solar Projects in Mexico
Published on 03/05/2026 at 13:00, 52 minutes ago Field Work Identifies New Mineralized Trend and Additional Gold Targets at Golden Rose
Published on 03/05/2026 at 13:43, 9 minutes ago Healthcare specialist SHS Capital exits AMW, a leading specialty pharma company, and continues partnership by reinvesting with its current fund as part of a syndicate of investors
Published on 03/05/2026 at 13:25, 27 minutes ago Huawei and SOLUM Unveil Shop-in-Shop Smart Converged Network Solution to Accelerate Retail Intelligence
Published on 03/05/2026 at 13:06, 45 minutes ago HENSOLDT acquires Nedinsco and expands its European presence
Published on 03/05/2026 at 13:05, 47 minutes ago Norgine announces £23 million new investment as part of more than £50 million committed to expanding medicines manufacturing in Wales
Published on 03/05/2026 at 13:00, 52 minutes ago Huawei Launches AI Data Platform to Bridge Models and Business Value
Published on 03/04/2026 at 23:50, 14 hours 2 minutes ago Total number of voting rights and shares making up the share capital at February 28, 2026
Published on 03/04/2026 at 18:00, 19 hours 52 minutes ago Disclosure of Share Capital and Voting Rights as of February 28, 2026
Published on 03/04/2026 at 17:45, 20 hours 7 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
